Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus high-dose Botox for chronic anal fissure
ACTRN12625001410448Phase 4Not yet recruiting
- Sponsor
- Eastern Health
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of botulinum toxin type A in chronic anal fissure (CAF) (2 arms), sponsored by Eastern Health. Primary endpoint: Anal fissure healing. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
chronic anal fissure (CAF)
Beyond the preview
Go deeper on ACTRN12625001410448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001410448.